SC
ABBV icon

Stratford Consulting’s AbbVie ABBV Stock Holding History

Stratford Consulting’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$207K Buy
2,715
+22
+0.8% +$1.87K 0.09% 52
2019
Q4 		$238K Buy
2,693
+22
+0.8% +$1.83K 0.08% 52
2019
Q3 		$202K Buy
+2,671
New +$183K 0.07% 53
2019
Q2 		– Sell
-2,565
Closed -$207K – 56
2019
Q1 		$207K Buy
2,565
+27
+1% +$2.21K 0.07% 51
2018
Q4 		$234K Buy
2,538
+22
+0.9% +$1.94K 0.09% 49
2018
Q3 		$238K Sell
2,516
-646
-20% -$61.3K 0.08% 45
2018
Q2 		$293K Buy
3,162
+23
+0.7% +$2.25K 0.11% 41
2018
Q1 		$297K Sell
3,139
-279
-8% -$30.6K 0.11% 40
2017
Q4 		$331K Buy
3,418
+19
+0.6% +$1.79K 0.12% 41
2017
Q3 		$302K Buy
3,399
+25
+0.7% +$1.9K 0.11% 41
2017
Q2 		$245K Sell
3,374
-585
-15% -$39.3K 0.1% 39
2017
Q1 		$258K Buy
3,959
+29
+0.7% +$1.82K 0.1% 45
2016
Q4 		$246K Buy
3,930
+24
+0.6% +$1.47K 0.11% 46
2016
Q3 		$246K Sell
3,906
-872
-18% -$56.5K 0.11% 44
2016
Q2 		$296K Sell
4,778
-770
-14% -$46.9K 0.13% 41
2016
Q1 		$317K Buy
5,548
+37
+0.7% +$2.06K 0.15% 41
2015
Q4 		$326K Buy
5,511
+29
+0.5% +$1.67K 0.17% 44
2015
Q3 		$298K Buy
5,482
+26
+0.5% +$1.69K 0.16% 43
2015
Q2 		$367K Sell
5,456
-459
-8% -$30K 0.18% 39
2015
Q1 		$346K Sell
5,915
-245
-4% -$14.8K 0.17% 44
2014
Q4 		$403K Sell
6,160
-64
-1% -$4.04K 0.21% 40
2014
Q3 		$360K Buy
6,224
+32
+0.5% +$1.78K 0.19% 42
2014
Q2 		$349K Buy
6,192
+32
+0.5% +$1.68K 0.18% 42
2014
Q1 		$317K Buy
6,160
+28
+0.5% +$1.42K 0.17% 43
2013
Q4 		$324K Buy
6,132
+29
+0.5% +$1.43K 0.18% 43
2013
Q3 		$273K Buy
6,103
+37
+0.6% +$1.64K 0.17% 43
2013
Q2 		$251K Buy
+6,066
New +$265K 0.15% 43

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Stratford Consulting's ABBV Position: Q1 2020 in Review

Stratford Consulting increased its AbbVie (ABBV) stake by 0.82% in Q1 2020, buying an estimated $1.87K and bringing the position to 2,715 shares worth $207K. The position accounts for 0.09% of the portfolio, ranked #52.

Stratford Consulting first reported a position in ABBV in Q2 2013 and has held it in 27 quarters since. The position peaked at $403K in Q4 2014. 2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

  • Stratford Consulting held 2,715 shares of AbbVie worth $207K as of Q1 2020.
  • Stratford Consulting bought 22 AbbVie shares in Q1 2020, an estimated $1.87K.
  • AbbVie made up 0.09% of Stratford Consulting's portfolio in Q1 2020, its #52 holding.
  • Stratford Consulting first reported a position in AbbVie in Q2 2013 and has held it in 27 quarters since.
  • Stratford Consulting's AbbVie position peaked at $403K in Q4 2014.
  • 2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Stratford Consulting's 13F filing for Q1 2020, filed 11 May 2020.